Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Cost-effectiveness of umeclidinium bromide 62.5µg or alternative LAMA plus ICS/LABA in COPD Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017
Interaction between tiotropium bromide and olodaterol in small human airways Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Cost effectiveness of umeclidinium bromide 62.5µg plus ICS/LABA versus ICS/LABA in COPD Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017
Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Tiotropium bromide: Efficacy and safety in complex treatment of COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Rapid plasma hydrolysis of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
The preclinical urinary and renal safety profile of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018